Randomized controlled trials have resulted in a significant reduction in cardiovascular events and mortality following treatment with EMPA and another SGLT-2 inhibitor, canagliflozin; as reported in Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus patients (EMPA-REG OUTCOME) and The CANagliflozin cardioVascular Assessment Study (CANVAS) [6]. The gene discussed is SLC5A2; the disease is diabetes mellitus.